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Inflammation is a common denominator of diseases. The complement system, an intrinsic
part of the innate immune system, is a key driver of inflammation in numerous disorders.
Recently, a family of proteins has been suggested to be of vital importance in conditions
characterized by complement dysregulation: the human Factor H (FH) family. This group
of proteins consists of FH, Factor H-like protein 1 and five Factor H-related proteins. The
FH family has been linked to infectious, vascular, eye, kidney and autoimmune diseases. In
contrast to FH, the functions of the other highly homologous proteins are largely unknown
and, hence, their role in the different disease-specific pathogenic mechanisms remains
elusive. In this perspective review, we address the major challenges ahead in this
emerging area, including 1) the controversies about the functional roles of the FH
protein family, 2) the discrepancies in quantification of the FH protein family, 3) the
unmet needs for validated tools and 4) limitations of animal models. Next, we also discuss
the opportunities that exist for the immunology community. A strong multidisciplinary
approach is required to solve these obstacles and is only possible through interdisciplinary
collaboration between biologists, chemists, geneticists and physicians. We position this
review in light of our own perspective, as principal investigators of the SciFiMed
Consortium, a consortium aiming to create a comprehensive analytical system for the
quantitative and functional assessment of the entire FH protein family.
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Fronti“When you can measure what you are speaking about,
and express it innumbers, you knowsomething about it”
– William Thomson, 1st Baron KelvinINTRODUCTION: THE FACTOR H
PROTEIN FAMILY
The complement system forms a major arm of innate immunity
and is of importance to fight invading pathogens (1). It consists
of over 50 proteins that activate each other in a fixed order via
three distinct pathways; the classical (CP), lectin (LP) and
alternative pathway (AP), which all lead to cleavage of C3 and
C5. This results in labeling of pathogens with C3b, attraction of
immune cells via the anaphylatoxins C3a and C5a, and
formation of the membrane attack complex [reviewed in (2)].
While the complement system is traditionally seen as a plasma
system, recent studies also describe its importance locally,
perhaps even inside cells (3). In health, the complement system
is tightly regulated to prevent unwanted activation, inflammation
and tissue damage. It has long been known that complement
dysregulation contributes to various inflammatory and
autoimmune diseases (4–6). A number of membrane-bound
and fluid phase regulators ensure that the complement system
is well-controlled (reviewed in (7)). Here, we will focus on the
main regulator of the alternative pathway, namely Factor H
(FH). FH can distinguish between self and non-self, and prevents
complement activation both on cellular surfaces and in the
circulation (8). More specifically, FH can function as a co-
factor for Factor I (FI)-mediated proteolysis of C3b into iC3b,
a molecule that cannot further propagate pathway activation. FH
can also compete with Factor B (FB) to inhibit formation of the
C3(H2O)B fluid phase tickover complex. In addition, FH
promotes the decay of existing C3bBb-complexes (i.e., the C3-
convertase), as well as the C4bC2aC3b and C3bBbC3b-
complexes (i.e., the C5 convertases). FH is composed of 20
repetitive units, called complement control protein (CCP)
domains, in a “beads on a string” configuration. The CCPs are
~65 amino acids in length and contain two invariant disulfide
bonds. The FH N-terminal (CCPs 1–4) is important for decay
accelerating activity and co-factor activity, while the internal
region (CCPs 6–8) and the C-terminal (CCPs 19–20) are neededviations: aHUS, Atypical hemolytic uremic syndrome; AMD, Age-related
lar degeneration; ANCA, Anti-neutrophil cytoplasmic antibody; AP,
ative pathway; AU, Arbitrary units; BLAST, Basic local alignment search
C3G, C3 glomerulopathy; CCP, Complement control protein; CFH,
lement Factor H gene; CFHR, Complement Factor H-related genes; CP,
cal pathway; CRP, C-reactive protein; FB, Factor B; FH, Factor H; FHL-1,
H-like 1; FHR, Factor H-related protein; FI, Factor I; FISH, Fluorescence in
ybridization; IgAN, Immunoglobulin A nephropathy; LP, Lectin pathway;
Monoclonal antibody; mCFH, Murine complement Factor H gene; mCFHR,
e complement Factor H-related gene; mFH, Murine Factor H; mFHR,
e Factor H-related protein; NLRP3, NOD-, LRR- and pyrin domain-
ining protein 3; PTX3, Pentraxin-3; RCA, Regulators of complement
ation gene cluster; SLE, Systemic lupus erythematosus; TMA,
botic microangiopathy.
ers in Immunology | www.frontiersin.org 2for host/ligand recognition and thus also for complement
regulation on host surfaces (9–11). The human gene for FH is
located on chromosome 1 within the Regulators of Complement
Activation (RCA) gene cluster. The RCA gene cluster contains
more than sixty genes and includes a ~700 Kb region in which
FH as well as the Factor H-Related (FHR) proteins are encoded
(described below). The complement FHR genes (CFHR) contain
several repeating regions believed to have resulted from large
genomic duplication events leading to the production of FHR
proteins with partly similar domains to FH (12).
FH like-1 (FHL-1) is an alternatively-spliced version of FH
and shares the first 7 CCP domains of FH before terminating
with a unique four amino acid C-terminal tail. FHL-1 contains
the C3b binding and regulatory domains of FH and thereby
retains the regulatory function of FH. Also, since FHL-1 contains
the CCP domains 6–7 of FH, it is assumed that FHL-1 shares
some of the FH ligands and the ability to regulate complement
on certain surfaces (13–15). Indeed, FHL-1 has been shown to
bind similar ligands as FH such as C-reactive protein (CRP),
pentraxin 3, heparin and malondialdehyde epitopes (16–18).
Nevertheless, clear differences exist between these two proteins
such as the extra binding domains in FH (CCP 8–20), the
distinctive three-dimensional conformation of both proteins,
and the unique C-terminus of FHL-1. This suggests that FH
and FHL-1 also bind to distinct ligands expressed in certain
tissues. Moreover, it has been implied that FHL-1 has a local and
tissue specific role instead of a systemic function like FH (13).
Humans also have five FHR proteins; FHR-1, FHR-2, FHR-3,
FHR-4 and FHR-5, whose functions are poorly characterized
(described in more detail in (8)). Yet, their importance is shown
by the causal link between genetic alterations in CFHR and various
diseases (i.e., IgA nephropathy (IgAN) (19–23), age-related
macular degeneration (AMD) (24–28), invasive meningococcal
disease (29–31), atypical hemolytic uremic syndrome (aHUS) (32)
and C3 glomerulopathy (C3G) (33). All FHR proteins share a high
degree of similarity with FH in their N-terminus (varying between
36 and 94%) and their C-terminus (varying between 36 and 100%)
(34). Notably, the N-terminus of the FHR proteins resembles
CCPs 6–8 of FH, while the C-terminus is similar to CCPs 19–20 of
FH. FHR-5 is an exception to this, since FHR-5 shares homology
to CCPs 6–7 as well as CCPs 10–14 and CCPs 19–20 of FH. The
homology of the FHR proteins to the surface recognition domains
of FH enables these proteins to bind similar ligands on surfaces
including heparin and C3 activation fragments such as C3b or C3d
(32). However, since all FHR proteins lack the domains of FH
responsible for the regulatory activity, the FHR proteins will,
unlike FH, most likely not provide protection to these surfaces
against complement attack. The current belief is, therefore, that
the FHR proteins antagonize the ability of FH to regulate
complement activation (35). Furthermore, some FHR proteins
can form dimers. FHR-1, FHR-2, and FHR-5 contain a
dimerization motif in their N-terminal domains, while in FHR-3
and FHR-4 this motif is missing. This would enable FHR-1, FHR-
2, and FHR-5 to form both homodimers and heterodimers.
Accordingly, structural and sequence analyses suggested that, in
addition to homodimers, FHR-1 can form heterodimers withMarch 2021 | Volume 12 | Article 660194
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be formed in sera partially or totally deficient in FHR-1 (36).
However, recently, another study suggested that only four dimers
occur in circulation: homodimers of FHR-1, FHR-2, and FHR-5,
as well as FHR-1/FHR-2 heterodimers (37). Further studies are
therefore needed to confirm the exact nature of the dimer
composition, as well as the precise function of these dimers.BRIEF DESCRIPTION OF THE HISTORY
In hindsight, the earliest publication about the FH family was in
1965, when Nilsson and Muller-Eberhard initially isolated FH
from human serum and identified this novel protein as b1H
globulin (38). Yet, it wasn’t until 1976 that two groups
independently of each other discovered the C3b inhibitory
activity of FH as well as its regulatory activity on the C3-
convertase (39–41). In 1983, regulation of C5 convertases by
FH was first described (42). Finally, in 1988, the genetic code of
FH and its amino acid sequence were identified (43). This
discovery was essential to uncover the structure of FH as
discussed above. At around the same time of this
breakthrough, Schwaeble et al. demonstrated the expression of
an additional smaller truncated form of FH in the human liver,
which we now know as FHL-1 (44). In 1989, the same group
demonstrated that FHL-1 had FI-cofactor activity (45). In the
end, in 1991, FH and FHL-1 were shown to be derived from the
same gene by a process of alternative splicing (46, 47).
One of the earliest mentions on any of the FHR proteins was
in a paper describing the isolation of murine FHR proteins by
Vik et al. in 1990 (48). Due to the extensive number of large
genomic duplications between the exons of CFH and the CFHR
genes, determining the genomic positions of the human CFHR
genes was challenging and was performed throughout the early
to mid-1990’s. In 1991 and 1992, mRNA transcripts encoding for
FHR-1, FHR-2 and FHR-3 were revealed (47, 49–51). Expression
of FHRs on protein level were characterized and described soon
after (44, 50, 52). The position of CFHR2 was the first of the FHR
proteins to be determined when it was identified within the
region between CFH and Factor XIII (53). In the next years, the
other three CFHR genes were mapped within the RCA cluster
between CFH and CFHR2 (54). However, due to the high
sequence resemblances between these genes, the determination
of their exact positioning was not possible. The last CFHR gene
discovered was for FHR-5, which was first described at protein
level in 2001 in studies of immune-complex-mediated kidney
diseases (55, 56). Finally, the genetic location of CFHR5 was
determined using fluorescence in situ hybridization (FISH),
radiation hybrid mapping and BLAST alignment (57).
Ultimately, it wasn’t until 2002 that the genomic segment
containing the CFH and CFHR gene family was confirmed and
to have the gene positions from centromere to telomere: CFH,
CFHR3, CFHR1, CFHR4, CFHR2, CFHR5 (a schematic overview
of the genomic organization of the CFH gene family is provided
in (35)). Furthermore, nowadays other forms of the FH protein
family have also been described, namely the alternatively splicedFrontiers in Immunology | www.frontiersin.org 3forms of CFHR4 named FHR-4A and FHR-4B leading to a total
of 8 proteins that are encoded by the human CFH and CFHR
gene family (excluding the different glycosylation variants as well
as the homo- and heterodimers) (an outline of the protein
structure of the FH family is provided in (8, 35, 58).FACTOR H AND THE RELATED PROTEINS
IN DISEASE
In recent years, numerous conditions have been associated with
mutations or polymorphisms in the CFH gene family [an
overview is provided in (32, 35, 59)]. These findings support
the notion that complement dysregulation due to alterations in
the FH family are a unifying pathogenic feature of various
pathologies. Deciphering the pathogenic mechanism by which
this protein family leads to disease is crucial for establishing the
right diagnosis and therapeutic interventions. Despite the
association of genetic variants in the CFH gene family with
diseases, little is known regarding the biological processes leading
to inflammation and tissue injury. Understanding the molecular
mechanisms behind these genetic associations is challenging and
represents an area of intense research. Notably, the disease-
associated genetic variants in the CFHR1-5 are particularly
difficult to interpret due to the lack of knowledge regarding the
biological role of the FHRs. We and others have shown the
existence of genotype-phenotype correlations between gene
variants in the CFH-CFHR1-5 and complement-mediated
diseases demonstrating that, although the same genes associate
with various diseases, the molecular mechanisms behind these
associations are specific of each condition (15, 59–61). In this
context, the studies performed with FH, the best-known member
of the family, were the first ones to illustrate such genotype–
phenotype correlations. Mutations causing plasma FH
deficiencies were amongst the first CFH alterations described.
When these CFH mutations are present in homozygosis or
compound heterozygosis they lead to complete FH deficiency,
which cause massive complement activation in fluid phase, and
are commonly associated with C3G, a heterogeneous
histopathological entity characterized by glomerular C3
accumulation (62). However, when the null CFH alleles are in
heterozygosis they only lead to partial FH deficiencies, and are
equally associated with C3G as well as other diseases such as
aHUS, AMD and IgAN. In this scenario, the combination with
other genetic, acquired and/or environmental risk factors that
are specific for each disease determines the final phenotype
outcome. Interestingly, missense mutations within the C-
terminus of FH are prototypical of aHUS and cause an
inappropriate regulation of complement on endothelial
surfaces leading to tissue damage, but without altering
complement regulation in the fluid phase (63–66).
In addition to CFH, strong associations between genetic
modifications in CFHR1-5 and pathologic outcome have also
emerged (32). Amongst the disease-associated CFHR1-5
variants, genomic rearrangements leading to deletions,
duplications, or hybrid genes are the most remarkable andMarch 2021 | Volume 12 | Article 660194
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the deletion of CFHR3 and CFHR1, which has a variable allele
frequency between 0–55% in various ethnic groups (67).
Moreover, this common gene variant is associated with
protection against the development of AMD and IgAN, while
it increases the susceptibility for aHUS (due to anti-FH
autoantibodies) and systemic lupus erythematosus (SLE) (21,
24, 68, 69). These different disease associations highlight the
relevance of the context in defining the effect of the FHR-1 and
FHR-3 deficiency, illustrating those situations where the
promotion of complement activation by the FHR proteins may
be detrimental (i.e., Bruch´s membrane and mesangium) or
where it may be beneficial (i.e., apoptotic cells). Another
captivating type of a genomic rearrangement of the CFHRs is
the duplication of the dimerization domains in FHR-1, FHR-2 or
FHR-5. These CFHR variations are exclusively associated with
C3G (33, 70–73). In this case, the resulting proteins are gain-of-
function mutants that present an increased avidity for their
ligands (36). Hence, these mutant proteins are postulated to
out–compete the binding of FH to C3b deposited on surfaces and
impair complement regulation more efficiently than the
corresponding wild-type proteins (32, 36).
Besides genetic modifications, systemic levels of FHRs may
also be crucial in disease processes. In anti-neutrophil
cytoplasmic antibody (ANCA)-associated glomerulonephritis,
increased systemic levels of FHR-1 were found compared to
healthy controls (74). Additionally, FHR-1 levels were shown to
weakly correlate with lower renal function and the percentage of
relapses increased with growing FHR-1 concentrations. In IgAN,
two groups independently of each other reported that plasma
levels of FHR-1 and the FHR-1/FH-ratio are elevated in these
patients and associate with progressive disease (75, 76). In
contrast, plasma FHR-5 and the FHR-5/FH-ratio were not
associated with progressive disease (76). However, higher FHR-
5 levels in IgAN did associate with histological disease severity.
In aHUS, plasma FHR-3 levels were demonstrated to be elevated
compared to controls even when taking the CFHR3 genotype
into account (77). Also, the aHUS-risk CFH–CFHR3–CFHR1
haplotype was shown to be associated with increased plasma
levels of FHR-3, suggesting that an imbalance between FH and
FHR-3 concentration may predispose individuals to aHUS.
Recently, increased systemic FHR-4 levels were shown to be
strongly associated with AMD (28). This is the first time that
FHR-4 has been associated with a disease. A genome-wide
association study revealed that an intronic variant in CFHR4
correlated with systemic complement activation in AMD
patients and associated with an increased risk of AMD
development (26). A follow-up study demonstrated that the
CFHR4 variant was associated with higher levels of FHR-4
(28). Moreover, circulating FHR-4 levels and the FHR-4/FH-
ratio were demonstrated to be elevated in AMD compared to
controls, and the protein co-localized with complement
activation products in choriocapillaris beneath the retina.
In addition to autoimmune diseases, the FH family has also
been known to be involved in infections (78). Pathogens evade
complement attack by recruiting complement regulators such asFrontiers in Immunology | www.frontiersin.org 4FH onto their surface, and it is suggested that the FHR proteins
have evolved as decoys to reduce the amount of FH that is
acquired by the microbes (35, 79). An illustrative example of this
situation was described by Caesar et al., who showed that FHR-3
competes with FH for the binding of a FH-binding protein on
Neisseria meningitidis, acting as a FH antagonist, which explains
why the CFH haplotype 3, characterized by low FH and high
FHR-3 plasma levels, is associated with lower susceptibility to
meningococcal disease (78, 80). However, in contrast, the
deletion of CFHR3 and CFHR1 was found to be associated
with better survival in patients with bacterial meningitis (81).
Altogether, this demonstrates the complex and multifaceted roles
of the FH family in infections.
Altogether, the associations of the FH family with these
diseases illustrate the relevance of the delicate balance between
the different family members. Notably, the ratio between the
levels of the regulator FH and the FHR proteins (i.e., FHR-1,
FHR-3, FHR-4 and FHR-5) seems crucial in determining the
outcome. Hence, either genetic or environmental factors altering
the protein levels or the functionality of these proteins will have
an impact on complement regulation and will define the
susceptibility for the development of pathological conditions.MAJOR CHALLENGES
In the last few decades, major strides have been made in our
understanding of the FH protein family. From these findings an
appreciation has emerged of the vast complexity of this group of
proteins as well as of the monoclonal antibodies developed to
specifically detect the different members of the Factor H protein
family. Unfortunately, we still face multiple unmet challenges.
Many of these involve the need for reagents and models to better
understand the function of FHR proteins in health and
pathology. Here, we will discuss four specific unmet challenges
that need to be resolved (Figure 1).
Controversies in Functional Roles
The biological function of the FH protein family has been elusive.
While it is clear that FH is a potent inhibitor of the complement
system, and most data point towards a similar role for FHL-1, the
functions of the more recently discovered FHR proteins are less
well characterized and therefore remain uncertain. Initially, it
was suggested that certain family members (e. g. FHR-1, FHR-3
and FHR-4) had no specific function or, at least, no essential
function within the complement system. This rationale was
largely based on the high frequency of CFHR gene deletions in
the general population and the high homology among these
proteins, suggesting some degree of functional redundancy.
Instead, genetic studies revealed that alterations in the CFHR
genes were indeed associated with pathology (described above),
thereby providing the first piece of evidence that FHR proteins
could be key pathogenic drivers of human disease. Since the
pathogenesis of these diseases involve complement
dysregulation, initial functional studies primarily focused on
the potential regulatory functions of the FHR proteins. As aMarch 2021 | Volume 12 | Article 660194
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proteins have complement regulatory capacity or not. Results
from these earlier studies indicated that the FHR proteins
primarily functioned as complement regulators at specific steps
of the cascade, while this concept was contested by later studies
(82). Specifically, first the interaction of FHR proteins with C3
was investigated by functional studies, as an indicator of their
potential complement inhibiting capacity, since the related
proteins were assumed to be functional analogues of FH.
Indeed, FHR-3 and FHR-4B were able to bind to the C3d
region of C3b (83). Yet, when FHR-3 and FHR-4 were first
studied for their effect on Factor I-mediated C3b inactivation,
direct co-factor activity was very weak and only detectable at very
high, and non-physiological, concentrations (i.e., 400 µg/ml).
Moreover, the addition of FHR-3 and FHR-4 also enhanced the
inhibitory activity of FH. A later study demonstrated a small
inhibitory effect for FHR-3 in the hemolysis assays using FH-
depleted serum (84). The regulatory effect of FHR-3 was shown
to be based on cofactor activity, although supraphysiological
concentrations were once again used. In contrast, others could
not show any significant cofactor activity for FHR-4, even at high
concentrations (i.e., 650 µg/ml) (85). In this study, FHR-4 did
slightly enhance the inhibitory activity of FH. Later, FHR-2 was
shown to bind C3b and C3d (86). While no cofactor or decay
accelerating activity was found for FHR-2, it was shown to
inhibit the activity of the C3bBb-convertase. For FHR-5, weak
cofactor activity and fluid phase C3-convertase inhibiting activity
were reported, once again at very high concentrations (87). FHR-
5 was also found to inhibit both the C5-convertases of the CP and
AP in an artificial, bead-based in vitro model (88). In these latter
assays, the effective FHR-5 concentrations were close to serum
levels measured in samples from healthy donors and patients
with glomerulonephritis (37, 76, 87, 89). In conformity, FHR-5Frontiers in Immunology | www.frontiersin.org 5produced by glioblastoma cells was also shown to act as a co-
factor of Factor I and inhibit terminal pathway activation,
although solely at high concentrations (90). Likewise,
inhibition at the C5 level and/or the terminal pathway has also
been reported for FHR-1, FHR-2 and FHR-3 (84, 86, 91).
Fittingly, in a mouse model of a neurological autoimmune
disease, injection of FHR-1 expressing neural stem cells
ameliorated brain injury. Human FHR-1 was shown to protect
astrocytes from complement activation by inhibiting the
formation of the membrane attack complex (92). However,
others have not been able to find any significant inhibiting
activity of FHR-1 on the terminal pathway (36, 93–95).
Despite these initial studies, it has been very difficult to
reconcile the reported regulatory activities of FHR proteins
with their structures, especially considering the lack of
structural homology of the related proteins with the regulatory
domains of FH. In recent years, accumulating data strongly
indicated a role for the FHR proteins as promoters of
complement activation that stands in contrast to the regulatory
function of FH and FHL-1. The study by Hebecker and Józsi was
the first to challenge the paradigm, demonstrating that, by
binding C3b, FHR-4 in fact enhances alternative pathway
activation (85), a mechanism which was also suggested
previously by Närkiö-Mäkelä et al. (96). This property of FHR-
4 was recently exploited to overcome complement resistance of
HER-2 positive tumor cells by applying FHR-4 based
immunoconjugates (97). Studies by Tortajada et al. and
Goicoechea et al. soon followed and described another
mechanism, namely de-regulation by FHRs through
competition with FH. FHR-1, FHR-2 and FHR-5 were shown
to form homo- and hetero-oligomeric complexes, while a C3G-
associated mutation in FHR-1 resulted in the duplication of the
dimerization domain leading to the formation of unusually largeFIGURE 1 | Four specific unmet challenges for the Factor H protein Family. The major challenges ahead in this emerging area are: 1. the controversies about the
functional roles of the Factor H protein family, 2. the discrepancies in quantification of the Factor H protein family, 3. the unmet needs for validated tools and 4.
limitations of animal models.March 2021 | Volume 12 | Article 660194
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C3 activation fragments (36, 71). Similarly, in IgAN, elevated
levels of FHR proteins were shown to be associated with
enhanced complement activation, while the absence of FHR-1
and FHR-3 was shown to decrease complement activation in
AMD. These functional roles are opposite to that proposed in
prior studies but are entirely consistent with the FHR structures,
wherein the homologies of FHR proteins with FH are in the
surface ligand-binding sites. Moreover, these studies strongly
suggest that FHR proteins compete with FH (and FHL-1)
mediated inhibition and thereby antagonize this key regulator
of the complement system. Overall, FHRs were indeed shown to
enhance complement activation both directly and indirectly (i.e.,
via competing with FH), thus emerging as “regulators of the
regulator” (34). Competition between FHRs and FH has been
described for several binding ligands. FHR-1, FHR-3, FHR-4 and
FHR-5 were all shown to compete with FH for binding to C3b, to
variable extent. Some of these differential effects may be related
to the different avidities also determined by homo- or
heterodimerization of FHR-1 and FHR-5 (36, 80, 84, 91). In
addition, FHR-5 has been shown to strongly inhibit the binding
of FH to the pentraxins (i.e., CRP and PTX3), as well as to
extracellular matrix and malondialdehyde-acetaldehyde epitopes
(98, 99). Subsequently, FHR-5 enhanced AP activation on these
ligands. For FHR-1, FHR-4 and FHR-5 it has been shown that,
by binding C3b, they can serve as a platform for the assembly of a
functionally active C3bBbP convertase, consequently enhancing
activation of the AP (85, 95, 98). Furthermore, FHR-5 can also
induce AP activating by the recruitment of properdin via the
CCPs 1-2 (99). Interestingly, in addition to modulation of the
AP, FHR-1 and FHR-4 were both shown to activate the CP as
well through the binding of CRP (i.e., FHR-1 the monomeric
form, and FHR-4 the native, pentameric CRP) (85, 95, 100).
More recently, FHR-1 and FHR-5 were shown to compete with
FH for binding to DNA and thus promote AP activation, as well
as to modulate both AP and CP activation on the surface of
necrotic cells via interactions with monomeric CRP and
PTX3 (101).
In conclusion, while complement inhibiting activity for some of
the FHR proteins was described, the reported inhibitory activities
were typically weak. More recent studies suggest that FHR proteins
represent pattern recognition molecules that promote rather than
constrain complement activation (35). To resolve the controversy,
these functions need to be studied further, using physiological
concentrations, and confirmed by independent research groups.
The reported discrepancies may be related to the various sources of
recombinant proteins used in the studies. In addition, the proteins
may display different, context-dependent activities. Besides the
function of the FH-family in the regulation of the complement
system, non-canonical functions such as regulating cellular
responses were described for FH, FHR-1 and FHR-3 (discussed
in detail elsewhere (102)). Losse et al. reported that FHR-1 can bind
to neutrophils via complement receptor 3 (CD11b/CD18), thereby
resulting in enhanced antimicrobial activity (103). Recently, FHR-1
was shown to activate the NLRP3 inflammasome via the EMR2
receptor on monocytes and by binding to necrotic cells (74).Frontiers in Immunology | www.frontiersin.org 6Furthermore, these mentioned controversies raise an additional
important question: How does the FH-family regulate
inflammation, and what are their ligands and are there FHR
protein receptors? Future studies need to define specific and
shared ligands among members of this protein family, as well as
conditions under which physiological or pathological functions are
displayed, or competition occurs.
Discrepancies in Quantification
Accurate analysis of the FH protein family is of utmost
importance for further deciphering of its function and role in
complement-mediated diseases. Accurate information on
physiological levels and the composition of the FH family
members is also vital for functional studies, since
supraphysiological levels can give misleading results. Yet,
precise analysis of FH and other complement system
components has proven to be challenging and systemic levels
for FH family members vary widely among different studies
(Table 1). These inconsistencies in levels are not only due to
differences in sample type (plasma vs serum or different
anticoagulants), storage (room temperature, 4°C vs -20°C or
-80°C) and pre-analytical sample handling between studies, but
also most likely caused by the use of different techniques (ELISA
vs mass spectrometry), protocols and reagents (113). Another
important explanation for the discrepancies in reported levels
could be differences in characteristics of the blood donors. Age
and gender have previously been demonstrated to significantly
impact complement levels and functionality in the healthy
population (114). Nevertheless, the impact of age and gender
on the FH protein family has not been extensively studied. In
healthy children, FHR-1, FHR-4A and FHR-5 levels were shown
to be slightly lower in children compared to adults, but only
FHR-5 levels were significantly associated with age (115). In
addition, no gender differences were found. Levels of FH, FHR-2,
and FHR-3 were similar to those found in adults (115). However,
when corrected for genetic factors, an age-dependent increase of
plasma levels of FH was seen for individuals aged 1 to 88 years
(105). Furthermore, even when laboratories use the same
technique, for instance ELISA, varying methods, reagents,
calibrators and antibodies are used. Moreover, when antibodies
are used, it is not always known whether these antibodies are
truly specific for the target antigen or if cross-reactivity with
other proteins may occur. Given that the FH protein family has a
high degree of similarity in amino acid sequence, it is very well
possible that antibodies against FH also cross-react with other
FH family members. As a result, large discrepancies in levels for
FH family members are observed between testing laboratories
thereby hampering correct interpretation and hindering the
comparison of results between studies. These inconsistencies in
levels indicate the urgent need for well-characterized and
standardized assays (116). Yet, validated and standardized
assays for quantitative and functional analysis are not (widely)
available for FH and its related proteins. Here, epitope mapping
can be extremely valuable to predict (potential) cross-reactivity
with other FH family members. The epitope location of a
monoclonal antibody (mAb) can be determined usingMarch 2021 | Volume 12 | Article 660194
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TABLE 1 | Previously published systemic levels of the Factor H protein family.
Protein Genotype Levels (µgml−1) N Reference
Total Factor H N.D. 400 ± 62 1004 (104)
N.D. 319.9 ± 71.4 358 (105)
N.D. 233.2 ± 56.7 63 (106)
N.D. 232.7 ± 74.5 1514 (107)











N.D. 349.0 (95%-CI: 339 - 359)




Total FHL-1 N.D. 47 ± 11.3 2 (108)








N.D. 94 [IQR: 70.5 – 119.6] 161 (76)
N.D. 1.63 ± 0.04 344 (109)
N.D. 26.5 ± 2.3 55 (74)








































N.D. 1.06 ± 0.53 21 (110)
N.D. 0.020 ± 0.001 344 (109)
Total FHR-4 N.D. 25.4 [IQR: 6.5 - 53.9] 11 (85)
N.D. 2.42 ± 0.18 344 (109)
N.D. 5.5 (95%-CI: 4.9 - 6.2)




FHR-4A N.D. 2.55 ± 1.46 129 (111)
FHR-4B N.D. Not detected ? (111)
Total FHR-5 N.D. 5.5 [IQR: 3.4 – 10.1] 13 (89)
N.D. 5.49 ± 1.55 344 (109)
N.D. 2.46 [IQR: 1.79 – 3.67] 158 (76)
N.D. 3.19 [IQR: 2.55 – 3.92] 153 (112)
Homodimers FHR-5 N.D. 1.66 ± 0.43 115 (37)An overview of the published systemic levels of Factor H, Factor H-like 1 and the five Factor H-related proteins in healthy controls. Specific information is provided per study on the genetic
background of the cohort, the number of subjects and whether they measured total levels, homo- or heterodimers. Data are presented as mean ± standard deviation (SD), mean with 95%
confidence interval (95%-CI) or median with interquartile range [IQR].
Poppelaars et al. The Factor H Protein Familyfragments consisting of CCP domains as previously described
(111). It is important to note that in contrary to the FHR
proteins, the functions of FH are well known and several
functional assays for FH exist, some of which currently are
being used in the clinic. FH-mediated decay-accelerating
activity can be measured in both ELISA as well as surface
plasmon resonance assays (117–119). The co-factor activity of
FH can be determined in both fluid-phase as well as on the cell
surface (120, 121). In addition, the full function of FH can be
addressed on cell surfaces using cell-based assays (13, 117, 119).
In order to provide insight into the magnitude of the
discrepancies in quantification of the FH protein family, we
determined systemic FH levels in samples from healthy
volunteers using seven commercially available ELISA’s (Table 2).
Levels of FH were evaluated in samples that were collected, stored
and handled exactly the same way. Next to those 10 samples, we
also included 2 samples obtained from the Complement EQA
Group. Both samples consist of a pool of serum samples derived
from 5 healthy individuals. The Complement EQA Group
committee aims to standardize complement analysis by
providing calibrator materials and collects, evaluates and
compares levels of complement components from different
testing facilities (see also below). It should be noted that within
the FH protein family, only quantitative analysis of serum levels of
FH is included in the standardization activities of the Complement
EQA Group. In 2009, this group was formally recognized and
became part of the IUIS (International Union of Immunological
Societies) Quality Assessment and Standardization Committee
(https://iuis.org/committees/qas/) (122). We chose plasma-EDTA
samples, since coagulation enzymes can also cleave complement
components with subsequent generation of activation products
(122). EDTA blocks the in vitro activation of the complement
system by Mg2+ and Ca2+ chelation. Citrate-based anticoagulants
are less useful (123). Moreover, heparin-plasma should not be used
since multiple members from the FH family are heparin-binding
proteins, hence heparin could interfere with the measurements. All
assays were performed in parallel by the same operator according
to the manufacturer’s protocols. In general, all %CV were ≤15%,
indicating low variation.
First, human purified FH protein dissolved in PBS wasmeasured
in all seven assays (Cat# A137, Complement Technology Inc., TX,
USA). None of the assays was able to ‘pinpoint’ this exact
concentration (not corrected for the extinction coefficient). The
assays from LSBio and USCN were not even able to detect purified
FH protein in PBS (Figure 2A). Next, a FH depleted sample wasFrontiers in Immunology | www.frontiersin.org 8measured as a negative control in all assays (Cat# A337,
Complement Technology Inc., TX, USA). As expected, most
assays did not detect FH in this sample. However, a FH
concentration of 377 µg/ml was measured in the FH depleted
sample using the USCN assay (Figure 2B). Subsequently, we
assessed systemic FH levels in plasma-EDTA samples derived
from 10 healthy controls. Results show large and significant
differences in FH levels between the seven assays used (P<0.0001).
No FH was detected with the LSBio assay (Figure 2C). In spite of
these differences in absolute FH levels between the assays, moderate
to high correlations were observed between the Abcam, Hycult,
Quidel, R&Dsystems and Sanquin assays regarding the FH levels
(Figure 2D). No correlation was observed between the USCN and
the other assay. For the LSBio assay, no correlation could be
calculated as no FH levels were detected with this assay. The FH
levels in the serum pool samples obtained from the Complement
EQA Group were comparable with the levels measured in the
healthy control panel. Again, no FH was detected using the LSBio
assay (Figure 2E). Lastly, calibrators were exchanged, except for the
Abcam and Quidel ELISAs, as not enough calibrator was provided
to be included in each assay as sample. Results show that the
calibrators from Hycult, R&Dsystems and Sanquin were
exchangeable, and yielded quantifiable and reliable levels. The
calibrators from LSBio and USCN were not recognized in all
other assays. In turn, the LSBio assay was not able to recognize/
measure any of the calibrators except its ‘own’ calibrator. The USCN
assay was able to recognize the calibrators fromHycult and Sanquin
(Figure 2F). Overall, the assays from Abcam, Hycult, R&Dsystems
and Sanquin were perfectly able to detect FH protein in the positive
control and did not detect FH in the negative control. Additionally,
the correlations between these assays were moderate to high. In
contrast, the results obtained with the LSBio and the USCN assay
suggest that these assays are not able to assess FH levels in samples
in a reliable manner. Nevertheless, even in the reliable assays, FH
levels obtained in the same sample set vary greatly. Given these
discrepancies, we can conclude that the absolute FH levels
determined with these assays, are probably not correct.
Considering the lack of quantification, it is suggested to provide
calibrators with these assays as arbitrary units (AU) only. In this
instance, these assays would then be able to detect differences in FH
levels between experimental groups (e.g., healthy vs disease), as long
as the same assay is used for all analyzed groups. In the end, the fact
that absolute FH levels vary greatly between assays may not be
surprising as calibrators from different sources were used in
their calibrations.TABLE 2 | Human Factor H ELISA’s included in the comparison analysis.
Company Name Cat# Lot# Website
Abcam Human FH ELISA ab137975 GR3261729-8 www.abcam.com
Hycult Biotech Complement FH, human, ELISA kit HK342 28643K0420 www.hycultbiotech.com
LSBio LSbio CFH LS-F21748 189699 www.lsbio.com
Quidel MicroVue FH EIA A039 184358 www.quidel.com
R&Dsystems CFH duoset DY4779 P240815 www.rndsystems.com
Sanquin Human FH ELISA No info* No info* www.sanquin.nl
USCN CFH ELISA kit SEA635Hu L200831651 www.uscnk.comMarch 2021 | Volu*The assay of Sanquin is only available as service. Samples can be sent to Sanquin for analysis.me 12 | Article 660194





FIGURE 2 | Assessment of Factor H levels in samples using seven different assays. (A) Assessment of Factor H (FH) purified protein in PBS (expected value is 690
µg/ml). (B) Assessment of FH levels in FH depleted serum. (C) Assessment of systemic FH levels in samples derived from healthy controls (n=10). Data are
represented as mean ± SEM. Data were analyzed using the one-way ANOVA (Graphpad Prism 8.4.2, San Diego, CA, USA). A p-value <0.05 was considered
significant. (D) Pearson r correlation coefficient. Pearson coefficients range from +1 to -1, with +1 representing a positive correlation of FH sample values between
assays, -1 representing a negative correlation of FH sample values between assays, and 0 representing no relationship. No correlation could be calculated for the
LSBio assay as no FH levels were obtained using this assay. (E) Assessment of FH levels in 2 serum pool samples obtained from the Complement EQA Group.
(F) Assessment of calibrators as sample in each assay. All calibrators were exchanged between the seven assays except for the Abcam and Quidel calibrator as not
enough calibrator was provided with these kits to be included in each assay as sample. FH, factor H; HCs, healthy controls; bdl, below detection limit.Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6601949
Poppelaars et al. The Factor H Protein FamilyFor the future, we therefore recommend that a uniform
protocol is used regarding sample collection, pre-analytical
sample handling and storage. For the assessment itself, it is
strongly recommended that standardized assays with a uniform
calibrator are used. When antibodies are used for quantification,
these must be characterized regarding specificity and cross-
reactivity with other proteins (see also below in the next
section). In this way, results can be produced that are robustly
comparable between different studies.Frontiers in Immunology | www.frontiersin.org 10Unmet Needs for Validated Tools
In 2016, Nature conducted a survey to understand scientist’s view
on the lack of reproducibility in research (124). When asked about
the cause, a proportion pointed towards poorly-characterized tools
leading to ambiguous findings, which results in an unstable
knowledge foundation that is then built upon. Since this survey,
different guidelines for in vitro and in vivo research have been
suggested, issued and published (125, 126). Characterization of
antibodies as well as validation of tools to quantify proteins is vitalTABLE 3 | Published antibodies that have been proposed to be specific for each of the Factor H-related proteins.
Characteristics Validation steps Use Source Ref.
FHL-1 Rabbit pAb IgG anti-human FHL-1 - Direct ELISA for FH and FHL-1.
- Double staining with specific FH antibody as well as
FH/FHL-1 antibody.
- Preincubation of the pAb with FHL-1 prior to IHC




FHR-1 Mouse mAb anti-human FHR-1
(Clone JHD10)
- Preincubation of the mAb with FHR-1 prior to IHC.
- IHC on material of patients with a combined CFHR1/3
deletion.
IHC, FC, WB. Non-commercial (74, 91)





FHR-2 Mouse mAb anti-human FHR-2 Unknown IF Non-commercial (99)
FHR-3 Mouse IgG2 mAb anti-human FHR-3
(Clone: RETC-2)
- Direct ELISA for recombinant FH and all FHRs.
- WB with recombinant FH, all FHRs and CFHR-3
deficient as well as normal serum.
- Mass spectrometry analyses of the immuno-




Mouse mAb anti-human FHR3
(Clone: HSL1)
- WB with normal human serum and CFHR3 deficient
serum.




FHR-4 Mouse IgG1 mAb anti-human FHR-4
(Clone 4.4)
- WB with recombinant FH and FHRs
- WB with normal human serum and CFHR3 as well as
CFHR4 deficient serum.
- WB of the immunoprecipitation by the mAb.
ELISA, WB. Non-commercial (111)
Mouse IgG mAb anti-human FHR-4
(Clone 4E9)
- WB with recombinant FHR-4 and normal human serum ELISA, WB. Non-commercial (28)
Mouse IgG mAb anti-human FHR-4
(clone 17)
- WB with recombinant FHR-4 and normal human serum ELISA, WB. Non-commercial (28)
Mouse IgG mAb anti-human FHR-4
(Clone 150)
- Preincubation of the mAb with FHR-4, FHL-1 prior to
IHC.
IHC, WB. Non-commercial (28)
FHR-5 Rabbit pAb IgG anti-human FHR-5 - Preincubation of the pAb with FHR-5 prior to IHC.
- Direct ELISA for C3c, iC3b and C3d with and without
FHR-5.
IHC, ELISA. (#81494-D01P; Abnova,
Taipei, Taiwan)
(128, 129)
Mouse mAb anti-human FHR-5
(Clone K2.254)
Unknown IHC, ELISA Non-commercial (55)





Mouse mAb IgG1 anti-human FHR-5
(clone 5.1)
- WB with recombinant FH and FHRs
- Direct ELISA for recombinant FH and all FHRs.
ELISA, WB Non-commercial (37)
Mouse mAb IgG1 anti-human FHR-5
(Clone 5.4)
- WB with recombinant FH and FHRs
- Direct ELISA for recombinant FH and all FHRs.
ELISA, WB Non-commercial (37)March 2021 | Volume 12 | ArAn overview of the published antibodies that are proposed to be specific for one of the Factor H-related proteins. Specific information is provided for each antibody in regards to their
characteristics, validation steps, application, source and the reference.
ELISA, enzyme-linked immunoassay; FC, flow cytometry; FH, Factor H; FHL-1. Factor H-like 1; FHR, Factor H-related protein; IF, immunofluorescence; IgG, immunoglobulin; IHC,
immunohistochemistry; mAb, monoclonal antibody; pAb, polyclonal antibody; WB, Western blot.ticle 660194
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considering the high risk of cross-reactivity due to their
homology. Yet, when looking at the specific antibodies that are
currently used in peer-reviewed publications, results on validation
of antibodies are not always provided (Table 3). Moreover,
whenever present, results on antibody validation are usually in
the supplementary data, a scientific habit that perhaps should be
reconsidered. Safeguarding accurate antibody validation should be
a main concern for all scientists, clinical end-users, industry,
journal publishers and antibody-linked research alike. Every
researcher has experienced research antibodies that don’t live up
to promises or expectations. Either because the antibody does not
recognize the desired target, or because they recognize a different
protein instead of, or as well as the desired target. Additional
problems include functionality of the antibody being limited to
certain applications. Too often the choice of an antibody is driven
by the number of citations it has in the literature, as scientists
falsely assume the antibody must have been validated previously,
enabling self-perpetuating artefacts. In this regard, we offer a
consensus report by the authors and hope to ignite further
discussion among the community to establish recommendations
for best practices to improve the reproducibility, validity and to
help advance research into the FH-protein family. Obviously,
these recommendations are not aimed at antibodies used for
mere in vitro experiments with purified components, but rather
for observational and intervention studies with a large sample size.
First of all, it would be advised to (i) reference and (ii) validate the
specific antibodies used for the FH protein family research field as
detailed as possible (130). We further suggest a best practice
protocol for the validation of all detection tools. Based on
previous guidelines, we suggest the following 4-step validation
protocol for antibodies against the FH protein family (131–134):
1. Show whole Western blot of target human/animals samples
detected with the antibody.
Value: Knowledge regarding the respective protein size(s).
Cave: Only applicable if the antibody is reactive inWestern blot.
2. Compare binding pattern of the antibody for ALL the different
known FH-protein family members (e.g. ELISA, Western blot
or Dot blot).
Value: Characterization of intra-protein family specificity.
Cave: Access to validation material can be restricted.
3. Test the antibody reactivity against either a.) non-depleted vs FH-
protein family members depleted human serum/plasma (if
available), b.) non-deficient cells vs target gene deficient cells
(if available) or c.) wildtype vs knockout animals (e.g., ELISA,
Western Blot or immunohistochemistry, if available).
Value: Species specificity of the antibody can be determined
independent from unknown protein modifications.
Cave: Access to validation material can be restricted.
4. Characterize the specificity of an antibody using
immunoprecipitation with subsequent mass spectrometry
analysis from the respective target tissue.
Value: Tissue specific cross reactions of the whole antibody
(even the Fc-part) will be deciphered.
Cave: Specialized collaborating laboratories are needed.Frontiers in Immunology | www.frontiersin.org 11It would be preferred to perform this 4-step validation
protocol in line with an already validated, antibody as a quality
control (if available). A single protocol will not match all
applications and researchers must ensure that the reported
validation holds true for their specific use. Overall, we are
convinced that va l idat ion of tools , together wi th
transdisciplinary collaboration and transparency within the
community will enable research to move forward and get one
step closer towards deciphering the mode of action of the FH-
protein family.
Limitations of Animal Models
Murine models have demonstrated high value for establishing
fundamental principles of complement biology (135). The
murine version of FH (mFH) was first identified in 1986
and is very similar in structure and function to the human
FH (136). As its human equivalent, mFH has a molecular
weight of around 155 kDa, has several glycosylation sites, is
positioned on chromosome 1 and is primarily produced by the
liver. The plasma concentration of mFH is estimated to be
similar to human FH, but an exact concentration of mFH has
not been determined yet (135, 136). Clear differences exist as
well between mFH and human FH. For instance, in contrast to
the human CFH gene, the mCFH gene does not have an
alternative splicing variant and thus no murine equivalent of
FHL-1 has been identified. Overall, The mCFH gene shares
63% of sequence identity with the human CFH gene (135).
Despite the differences in genes and protein structures across
mouse and human, it has been observed repeatedly that
essential activation and regulatory functions of this system
are retained across species. In accordance, genetically
deficient animals have provided a powerful tool to help
understand the function of FH.
The link between FH and disease is older than is frequently
reported. Høgåsen et al. described more than 25 years ago that a
hereditary deficiency of FH in pigs consistently led to the
development of lethal renal disease, namely C3G (137). These
findings were later confirmed in rodent models, demonstrating
that mice deficient in FH had uncontrolled complement
activation resulting in C3G (138). Interestingly, later studies
revealed that aged CFH-/- mice also develop retinal
abnormalities and visual dysfunction, resembling AMD (139).
The broad outlines are therefore clear, dysfunction of FH leads to
uncontrolled complement activation resulting in tissue injury
and thus causing disease. However, it was not clear what then
determines whether defects in FH cause one specific disease but
not the other. Animal models have helped to attribute the
different functions of FH to specific domains within the
protein, and thereby reveal specific genotype–phenotype
connections in FH that lead to either complement-mediated
thrombotic microangiopathy (TMA) or C3G and AMD. A study
by Pickering et al. uncovered that a homozygous FH deficiency in
mice leads to defective function of FH in the fluid-phase
triggering the development of C3G and AMD (138). In
contrast, loss of the SCR 16-20 region of FH impairs the
ability of FH to control complement activation on surfaces,March 2021 | Volume 12 | Article 660194
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models has helped significantly to understand the function of
complement proteins and their role in disease, especially for FH.
Animal models have barely been used to study the other
members of the Factor H family. As mentioned before, no
murine equivalent for the human FHL-1 exists. Furthermore,
the CFHR genes have arisen during evolution through
duplication events of the CFH gene (12). Extensive analysis of
the human CFH and CFHR gene loci using Alu/L1 repeat dating
established that these duplication events occurred after the
separation of rodent and primate lineages and therefore no
FHR orthologues exist in mice. More specifically, the mCFHR
genes differ in structure, domain composition, and sequence
from the human genes (32). Like the human FHR proteins, a
total of five murine CFHR genes have been suggested (mCFHR-
A, mCFHR-B, mCFHR-C, mCFHR-D and mCFHR-E) and
evidence for four mFHR proteins (FHR-B, FHR-C, FHR-D and
FHR-E) has been derived from mRNA transcripts isolated from
mouse liver (48, 140–143). However, altogether, this suggests
that direct comparisons between the human and mouse FHR
proteins is not informative and, therefore, any mouse FHR
homologs need to be identified, if they exist, by functional
studies before rodent models can be used to further study the
role of the FH protein family in human health and disease.
Alternatively, genetic engineering approaches could be used to
create a set of humanized transgenic mice to more closely mimic
the human FHR situation. Until that is achieved, the lack of
animal models remains a major barrier hindering the elucidation
of disease mechanisms and drug development. More
importantly, the absence of appropriate animal models stresses
the importance of appropriate human assays to correctly identify
and study the Factor H protein family in humans.THERAPEUTIC VALUE OF FH AND
DERIVATIVES IN COMPLEMENT-
MEDIATED DISEASES
The various disorders linked to the FH family tend to be difficult to
treat and some are even incurable. An obvious therapeutic strategy
for these diseases could therefore be the administration of (purified
or recombinant) FH to restore complement regulation. Indeed, both
in vitro and animal studies have demonstrated the therapeutic value
of FH (63, 137, 144–146). In CFH-/- pigs, a single dose of 5 mg/kg
porcine FH resulted in normalization of plasma C3 levels and
diminished systemic complement activation for almost 3 days (137).
In CFH-/- mice, both purified mouse and purified human FH led to
a rapid increase of plasma C3 levels and resolution of renal C3
deposition (144, 146). However, FH supplementation as a therapy
would require large amounts of biologically active protein due to
high circulating levels in healthy individual, making it labor and cost
intensive. Various strategies have been tested to resolve these
problems. Several groups have demonstrated successful
production of high yields of recombinant FH in different
expression systems (such as yeast and moss) as an alternative andFrontiers in Immunology | www.frontiersin.org 12economically viable method (147, 148). Others have created
derivates or fusion proteins from FH with enhanced
pharmacokinetic and pharmacodynamic properties. Smaller
constructs of FH have been created by combining the regulatory
domains (N-terminus) with the surface-recognition domains (C-
terminus) (121, 149, 150, 158). These FH constructs can regulate
complement in vivo, and effectively reverse renal C3 deposition and
restore plasma C3 levels in CFH-/-mice. However, the short half-life
of these constructs remains an important limitation. FH fusion
protein have also been engineered as a therapeutic approach (151–
153). Most extensively studied is the CR2-FH fusion protein, that
links the C3d binding domain of complement receptor 2 (CR2) to
the complement inhibitory domain of FH, thus ensuring targeted
regulation by FH at sites of complement activation (154). Treatment
with CR2-FH was beneficial in animal models of eye, kidney and
autoimmune diseases (155–157). Finally, local injection of FH (or
derivates) is another approach to circumvent the need for large
amounts of biologically active protein. A clinical trial investigating
the safety and effectivity of recombinant FH (GEM103)
administered through intravitreal injections for the treatment of
geographic atrophy secondary to dry AMD is currently on-going
(ClinicalTrials.gov identifier, NCT04246866).FUTURE PERSPECTIVE
A multidisciplinary approach is mandatory to overcome the
challenges mentioned above, and is only possible through
interdisciplinary collaboration between biologists, chemists,
geneticists and physicians. But, where to start? As suggested by
the quote of William Thomson, the authors of this paper
believe that we should essentially begin with quantifying the
levels and activity of the different members of the FH-family in
health and disease. Detection of the FH-protein family will
enable the scientific and clinical community to advance our
understanding of the role of the FH-protein family in infectious,
eye, kidney and autoimmune diseases, and potentially help treat
these disorders.CONCLUSION
As described, the FH-family, consists of FH, FHL-1 and the five
FHR proteins which are important regulators of the complement
system. Mutations and polymorphisms in the FH-family are
involved in several diseases, indicating a potential crucial role of
the FH-family in both health and disease. However, diagnosis and
therapy of these partially incurable pathologies is to-date not related
to the FH-protein family, due to a lack of fundamental knowledge of
(i) the molecular mechanisms leading to disease, (ii) unknown
functional, convincing principles of FH-protein family members,
(iii) absent standardized diagnostics and (iv) missing suitable
drug candidates. To overcome these challenges, an ardent
mu l t i d i s c i p l i n a r y app roach i s r equ i r ed th rough
interdisciplinary collaboration.March 2021 | Volume 12 | Article 660194
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Joźsi, Toonen, Pauly and the SciFiMed consortium. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.March 2021 | Volume 12 | Article 660194
